ESR1 and neoplasm: ESR1 pathogenic resistance alterations, which promote ligand-independent receptor activation, are rarely detected in the primary tumor and emerge primarily via clonal evolution under the selective pressure of prior endocrine therapy (mainly AI therapy)28,30–34.